In May 2024, the National Institute for Health and Care Excellence (NICE) released several significant updates regarding the assessment and recommendation of various medical treatments and technologies. These developments highlight NICE’s ongoing commitment to ensuring that NHS patients receive the best possible care through the adoption of clinically and cost-effective treatments. By evaluating and endorsing innovative medical solutions, NICE aims to address existing health disparities and improve overall patient outcomes across different medical conditions.
These updates cover a range of treatments, from new therapies for sickle cell disease and early breast cancer to home-testing devices for sleep conditions and plans for faster adoption of cutting-edge medical technologies. Each announcement reflects NICE’s rigorous approach to assessing clinical effectiveness and cost-efficiency, ensuring that both patients and the NHS benefit from the most advanced and reliable medical interventions available. The following summaries provide an overview of each major announcement made by NICE during this period, illustrating the significant impact of these decisions on patient care and the broader healthcare system.
Improved deal signals NICE recommendation of sickle cell treatment voxelotor: On May 3, 2024, NICE recommended voxelotor (Oxbryta, Pfizer) for treating haemolytic anaemia caused by sickle cell disease (SCD). This recommendation followed a reduction in voxelotor’s price, which addressed previous uncertainties regarding its cost-effectiveness. Approximately 4,000 patients in England are expected to benefit from this treatment, which will be funded through NHS England’s Innovative Medicines Fund. This decision underscores NICE’s commitment to addressing health inequalities and ensuring effective treatments for SCD patients.
Tests could lead to fewer people having unnecessary chemotherapy after surgery for early breast cancer: NICE recommended three tumour profiling tests (EndoPredict, Prosigna, and Oncotype DX) to help guide chemotherapy decisions for people with early breast cancer. These tests provide genetic information about breast cancer tumors, aiding in the treatment decisions for patients, particularly those who have been through menopause or men with ER- or PR-positive, HER2-negative early breast cancer. The recommendation aims to reduce unnecessary chemotherapy and its associated side effects, thus improving the quality of life for breast cancer patients.
Home testing devices could increase the number of people diagnosed with sleep condition: NICE recommended five home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (OSAHS). These devices, which can be used at home without the need for hospital visits, are less invasive and more comfortable, potentially increasing the detection rate of OSAHS. This condition, which affects around 5% of the UK population, is linked to serious health issues such as hypertension, diabetes, and heart disease. The new devices are expected to improve diagnosis rates and treatment outcomes for people with OSAHS.
NICE and NHS England announce plan to enable innovative tech to be adopted quicker: On May 23, 2024, NICE and NHS England announced new plans to expedite the adoption of innovative medical technologies within the NHS. The proposal outlines a pathway for MedTech developers to access NHS funding, ensuring that clinically and cost-effective products are rapidly introduced to improve patient outcomes. This initiative is part of the NHS Long Term Plan’s commitment to accelerate the uptake of selected innovative devices, diagnostics, and digital products, aiming to provide patients with the best available medical technologies.
These updates from NICE in May 2024 reflect a concerted effort to enhance patient care through the adoption of effective and innovative medical treatments and technologies. From recommending new treatments for sickle cell disease and breast cancer to improving the diagnosis of sleep conditions and expediting the adoption of medical technologies, NICE continues to play a crucial role in advancing healthcare in the UK. These initiatives not only ensure that patients receive timely and effective care but also demonstrate NICE’s dedication to optimizing healthcare delivery through evidence-based recommendations and innovative solutions.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
